$传奇生物(LEGN)$ Both drugs are linked to earlier deaths in patients who received Carvykti and Abecma, the FDA reviewers said, citing late-stage data the companies submitted from their respective clinical trials, CARTITUDE-4 and KarMMa-3.
At the end of the meeting, the FDA advisors are expected to vote if the risk-benefit profiles of the drugs are favorable for the suggested indication.